Related Experiment Video
Updated: Jun 5, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Oncogenetics of melanoma: basis for molecular diagnostics and therapy
Laura Held1, Thomas K Eigentler, Friedegund Meier
1Department of Dermatology, University of Tübingen, Germany.
Abstract:
Our understanding of oncogenetics and of the molecular mechanisms involved in melanoma development and signaling has dramatically changed in recent years. Today, melanomas are also classified based on molecular alterations. Emerging molecular therapies are targeted against specific mutations in melanoma. An example of targeted therapies is the successful treatment of KIT-mutant melanoma with the kinase inhibitor imatinib. Highly selective BRAF-inhibitors are likewise under clinical development and show encouraging clinical responses. An increasing number of targeted drugs will emerge in the coming years, based on molecular diagnostics and classification. The present article reviews signaling pathways in melanocytes and alterations in melanoma that are a prerequisite to understanding modern cancer therapies in melanoma.
Insights
Recent advances in melanoma oncogenetics have led to molecular classification and targeted therapies. Understanding these molecular pathways is crucial for developing new treatments like BRAF-inhibitors and imatinib for specific mutations.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Melanoma development and signaling pathways are increasingly understood at the molecular level.
- Melanoma classification now incorporates molecular alterations.
- Targeted therapies are emerging based on specific genetic mutations.
Purpose of the Study:
- To review signaling pathways in melanocytes.
- To discuss molecular alterations in melanoma.
- To provide a foundation for understanding modern melanoma cancer therapies.
Main Methods:
- Review of current scientific literature on melanoma oncogenetics and signaling pathways.
- Analysis of molecular alterations driving melanoma development.
- Examination of targeted therapies and their mechanisms.
Main Results:
- Melanoma classification is evolving to include molecular diagnostics.
- Targeted therapies, such as imatinib for KIT-mutant melanoma and BRAF-inhibitors, show clinical promise.
- An expanding array of targeted drugs is anticipated.
Conclusions:
- Understanding molecular pathways and alterations is essential for advancing melanoma treatment.
- Molecular diagnostics will increasingly guide personalized cancer therapies.
- The future of melanoma treatment lies in targeted molecular therapies.
Related Concept Videos
Cancer
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

